1---2name: managing-attention-deficit-disorders3description: Structures ADHD evaluation in children with behavioral rating scales and medication trials. Use when evaluating pediatric ADHD, interpreting Vanderbilt/Conners scales, or managing stimulant therapy.4---5
6# Managing Attention Deficit Disorders
7
8Structures the evaluation, diagnosis, and multimodal management of Attention-Deficit/Hyperactivity Disorder (ADHD) in children ages 4-18 using the AAP 2019 Clinical Practice Guideline, DSM-5 criteria, Vanderbilt Assessment Scales, evidence-based medication titration, and behavioral therapy coordination.
9
10## Why This Skill Exists
11
12ADHD is the most commonly diagnosed neurobehavioral disorder of childhood, affecting approximately 9.4% of U.S. children ages 2-17. Despite high prevalence, it is both overdiagnosed (in populations with access) and underdiagnosed (in girls, minorities, and underserved communities). The AAP 2019 guideline mandates structured diagnostic criteria with multi-informant rating scales, age-stratified treatment recommendations, and systematic titration protocols. This skill enforces the guideline-based diagnostic pathway and treatment algorithm to prevent both missed diagnoses and inappropriate stimulant prescribing.
13
14---
15
16## Checkpoint A — Intake Verification
17
18### Required Intake Questions
191. What is the child's age (4-18 for AAP guideline application)?
202. What are the primary concerns (inattention, hyperactivity, impulsivity, or combination)?
213. In which settings do symptoms occur (home, school, social, sports)?
224. When did symptoms first appear (must be present before age 12 per DSM-5)?
235. Are there academic problems (grades, IEP/504, retention)?
246. Is there a family history of ADHD, mood disorders, anxiety, or substance use?
257. Are there symptoms of comorbid conditions (anxiety, depression, ODD, learning disability, tic disorder, ASD)?
268. What is the child's sleep pattern (sleep deprivation mimics ADHD)?
279. Has the child had vision and hearing screening?
2810. Has the child been previously treated with medication for ADHD? What was the response?
29
30### Required Documents
31- Completed Vanderbilt Assessment Scales — Parent form AND Teacher form (or Conners-3, SNAP-IV)
32- Academic records (report cards, standardized test scores, teacher comments)
33- IEP/504 plan if applicable
34- Developmental history
35- Prior psychoeducational or neuropsychological testing (if done)
36- Vision and hearing screening results
37
38> DSM-5 requires symptoms in ≥ 2 settings. Teacher input is essential — do not diagnose ADHD without information from the school setting.
39
40---
41
42## Step 1 — DSM-5 Diagnostic Criteria
43
44### Diagnostic Requirements
45To diagnose ADHD, ALL of the following must be present:
46
471. **Symptom threshold**: ≥ 6 of 9 inattention symptoms AND/OR ≥ 6 of 9 hyperactivity-impulsivity symptoms (for age ≥ 17: ≥ 5 in either domain)
482. **Duration**: symptoms present for ≥ 6 months
493. **Age of onset**: several symptoms present before age 12
504. **Pervasiveness**: symptoms present in ≥ 2 settings (home + school)
515. **Impairment**: clear evidence that symptoms interfere with functioning
526. **Exclusion**: not better explained by another mental disorder
53
54### ADHD Presentation Types
55| Presentation | Criteria |
56|-------------|---------|
57| Predominantly inattentive | ≥ 6/9 inattention; < 6/9 H-I |
58| Predominantly hyperactive-impulsive | < 6/9 inattention; ≥ 6/9 H-I |
59| Combined | ≥ 6/9 in both domains |
60
61### Inattention Symptoms (9)
621. Fails to give close attention to details / careless mistakes
632. Difficulty sustaining attention in tasks or play
643. Does not seem to listen when spoken to directly
654. Does not follow through on instructions / fails to finish tasks
665. Difficulty organizing tasks and activities
676. Avoids or is reluctant to engage in tasks requiring sustained mental effort
687. Loses things necessary for tasks
698. Easily distracted by extraneous stimuli
709. Forgetful in daily activities
71
72### Hyperactivity-Impulsivity Symptoms (9)
731. Fidgets with hands/feet or squirms in seat
742. Leaves seat when remaining seated is expected
753. Runs about or climbs in inappropriate situations
764. Unable to play or engage in leisure activities quietly
775. "On the go" / acts as if "driven by a motor"
786. Talks excessively
797. Blurts out answers before questions are completed
808. Difficulty waiting turn
819. Interrupts or intrudes on others
82
83---
84
85## Step 2 — Vanderbilt Assessment Scale Interpretation
86
87### Parent Vanderbilt (NICHQ Vanderbilt Assessment Scale — Parent Informant)
88- 55 items covering: inattention (9 items), hyperactivity/impulsivity (9 items), ODD (8 items), conduct disorder (14 items), anxiety/depression (7 items), and performance (8 items)
89- Symptom scoring: 0 = Never, 1 = Occasionally, 2 = Often, 3 = Very Often
90- Symptom is "positive" if scored 2 (Often) or 3 (Very Often)
91- ADHD screen positive: ≥ 6 of 9 inattention AND/OR ≥ 6 of 9 H-I items scored ≥ 2
92- Performance impairment: ≥ 1 performance item scored 4 or 5 (somewhat/problematic)
93
94### Teacher Vanderbilt (NICHQ Vanderbilt Assessment Scale — Teacher Informant)
95- 43 items: inattention (9), H-I (9), ODD/conduct (10), anxiety/depression (7), academic performance (3), classroom behavior (5)
96- Same scoring and threshold criteria as parent form
97- Academic performance: scored 1-5 (excellent to problematic)
98
99### Concordance Analysis
100- Both parent AND teacher must show symptom endorsement for ADHD diagnosis
101- If only one setting endorses symptoms: investigate setting-specific factors (classroom structure, teacher expectations, home environment)
102- If discordant: consider alternative diagnoses (anxiety, learning disability, trauma)
103
104### Comorbidity Screening (Built Into Vanderbilt)
105- ODD screen: ≥ 4 of 8 items scored ≥ 2 + performance impairment
106- Conduct disorder screen: ≥ 3 of 14 items scored ≥ 2 + performance impairment
107- Anxiety/depression screen: ≥ 3 of 7 items scored ≥ 2 + performance impairment → warrants formal evaluation
108
109---
110
111## Step 3 — Age-Stratified Treatment (AAP 2019)
112
113### Ages 4-5 (Preschool)
114- **First-line**: parent-administered behavior therapy (evidence-based parent training programs)
115- **Medication**: methylphenidate may be prescribed if behavioral therapy is insufficient and symptoms cause moderate-to-severe functional impairment
116- Avoid amphetamines as first-line in this age group (less evidence)
117
118### Ages 6-11 (School-Age)
119- **First-line**: FDA-approved medication for ADHD AND/OR evidence-based behavioral therapy (preferably both)
120- AAP recommends medication + behavioral therapy as optimal combined treatment
121- Teacher-delivered behavioral strategies (daily report card, classroom accommodations)
122
123### Ages 12-18 (Adolescent)
124- **First-line**: FDA-approved medication with assent from the adolescent
125- Behavioral therapy should be offered, but medication is the primary treatment
126- Address driving safety, substance use risk, and organizational skills
127- Discuss medication continuity through transitions (college, employment)
128
129---
130
131## Step 4 — Medication Management
132
133### Stimulant Medications (First-Line)
134
135#### Methylphenidate Formulations
136| Formulation | Brand Examples | Duration | Starting Dose |
137|-------------|---------------|----------|---------------|
138| Immediate-release | Ritalin | 3-4 hours | 5 mg BID-TID |
139| Extended-release (OROS) | Concerta | 10-12 hours | 18 mg QAM |
140| Extended-release (beaded) | Ritalin LA, Aptensio XR | 8-10 hours | 10-20 mg QAM |
141| Transdermal patch | Daytrana | 10-12 hours | 10 mg/9 hr patch |
142| Liquid | Quillivant XR | 10-12 hours | 20 mg QAM |
143
144#### Amphetamine Formulations
145| Formulation | Brand Examples | Duration | Starting Dose |
146|-------------|---------------|----------|---------------|
147| Mixed amphetamine salts IR | Adderall | 4-6 hours | 5 mg QD-BID |
148| Mixed amphetamine salts XR | Adderall XR | 10-12 hours | 5-10 mg QAM |
149| Lisdexamfetamine | Vyvanse | 12-14 hours | 20-30 mg QAM |
150| Dextroamphetamine | Dexedrine | 4-6 hours | 2.5-5 mg BID |
151
152### Titration Protocol
1531. Start at the lowest recommended dose
1542. Titrate every 1-2 weeks based on response and side effects
1553. Use Vanderbilt Follow-Up scales (parent + teacher) to assess response
1564. Target: symptom reduction to < 6 positive items in affected domains + improved performance
1575. If one stimulant class fails (methylphenidate): switch to amphetamine class (and vice versa) before moving to non-stimulant
158
159### Non-Stimulant Medications (Second-Line)
160| Medication | Class | Starting Dose | Notes |
161|-----------|-------|---------------|-------|
162| Atomoxetine | NRI | 0.5 mg/kg/day × 3 days → 1.2 mg/kg/day | Onset 4-6 weeks; FDA black box: suicidal ideation monitoring |
163| Guanfacine XR | Alpha-2 agonist | 1 mg QHS | Sedation, hypotension; do not abruptly discontinue |
164| Clonidine XR | Alpha-2 agonist | 0.1 mg QHS | Similar to guanfacine; also treats tics |
165| Viloxazine XR | NRI | 100 mg QAM (6-11y); 200 mg QAM (12+) | Newer; less data on long-term outcomes |
166
167### Side Effect Monitoring
168- **Every visit**: weight, height, heart rate, blood pressure
169- **Appetite suppression**: most common side effect; counsel on high-calorie breakfast, after-medication meals, bedtime snacks
170- **Growth**: plot height and weight on growth chart at every visit; calculate height velocity annually; temporary growth deceleration is common
171- **Sleep**: stimulants may cause insomnia; consider earlier dosing, shorter-acting formulation, or melatonin adjunct
172- **Cardiovascular**: routine ECG NOT recommended for healthy children; obtain ECG only if cardiac history, family history of sudden death, or abnormal cardiac exam
173- **Tics**: stimulants may unmask but generally do not cause tics; tics are not an absolute contraindication
174- **Mood/behavior**: monitor for rebound irritability, emotional lability, new anxiety
175
176---
177
178## Step 5 — Behavioral and Academic Interventions
179
180### Evidence-Based Behavioral Therapy
181- **Parent training programs**: Triple P, Incredible Years, Parent-Child Interaction Therapy (PCIT)
182- **Classroom interventions**: daily report card (DRC), preferential seating, extended time, reduced homework load, frequent breaks
183- **Social skills groups**: peer interaction training (for children with social impairment)
184- **Organizational skills training**: for ages 8+ (homework routines, planner use, time management)
185
186### School Accommodations
187- Section 504 plan: ADHD qualifies as a disability under Section 504
188- IEP: if ADHD causes specific learning disability requiring specialized instruction (under IDEA category "Other Health Impairment")
189- Common accommodations: extended time on tests, preferential seating, reduced homework, movement breaks, behavior intervention plan
190
191---
192
193## Checkpoint B — ADHD Management Review
194
195- [ ] DSM-5 criteria systematically evaluated and documented
196- [ ] Symptoms confirmed in ≥ 2 settings (parent + teacher Vanderbilt)
197- [ ] ADHD presentation specified (inattentive, H-I, combined)
198- [ ] Comorbidities screened (ODD, conduct, anxiety, depression, learning disability)
199- [ ] Age-appropriate treatment initiated (behavioral therapy for 4-5; medication ± behavioral for 6+)
200- [ ] Medication selected, dose documented, titration plan specified
201- [ ] Side effect monitoring documented (weight, height, HR, BP)
202- [ ] Follow-up Vanderbilt scales collected from parent AND teacher
203- [ ] School accommodations addressed (504 or IEP discussion)
204- [ ] Driving safety discussed (if adolescent)
205- [ ] All [VERIFY] flags resolved or escalated
206
207---
208
209## Quality Audit
210
211| Item | Requirement | Pass? |
212|------|-------------|-------|
213| Multi-informant data | Parent AND teacher Vanderbilt/Conners completed | |
214| DSM-5 compliance | All 6 diagnostic criteria explicitly addressed | |
215| Presentation specified | Inattentive / H-I / Combined documented | |
216| Comorbidity screen | ODD, anxiety/depression at minimum screened | |
217| Age-appropriate Tx | Behavioral therapy first for 4-5; combined for 6+ | |
218| Titration plan | Starting dose, target, timeline for reassessment | |
219| Growth monitoring | Weight and height plotted at each medication visit | |
220| Vital signs | HR and BP documented at each medication visit | |
221| School coordination | 504/IEP addressed or discussed | |
222| No unexplained [VERIFY] tags | All flagged items resolved or escalated | |
223
224---
225
226## Guidelines
227
228- Follow AAP 2019 Clinical Practice Guideline: Diagnosis, Evaluation, and Treatment of ADHD in Children and Adolescents
229- Use DSM-5 criteria for ADHD diagnosis (APA 2013)
230- NICHQ Vanderbilt Assessment Scales: recommended by AAP for initial evaluation and follow-up monitoring
231- Stimulant titration: start low, go slow, use rating scales to measure response objectively
232- MTA study (Multimodal Treatment Study of ADHD): combined medication + behavioral therapy superior to either alone for school-age children
233- AAP: no routine ECG for ADHD medication initiation in healthy children without cardiac risk factors
234- FDA black box: atomoxetine — monitor for suicidal ideation, particularly in first months
235- Alpha-2 agonists: do not abruptly discontinue (rebound hypertension risk)
236- Substance abuse: treated ADHD reduces substance abuse risk; untreated ADHD increases it
237- ADHD is a chronic condition: treatment should not be discontinued without structured medication holiday and reassessment
238- This skill produces clinical documentation; it does not replace clinical judgment